Navigation Links
Drug rescues memory lost to Alzheimer's disease
Date:7/14/2009

Irvine, Calif., July 14, 2009 A drug similar to one used in clinical trials for treatment of rheumatoid arthritis and psoriasis has been found to rescue memory in mice exhibiting Alzheimer's symptoms.

The discovery by UC Irvine scientists offers hope that a new treatment may be on the horizon for people in the early stages of Alzheimer's, the leading cause of elderly dementia afflicting more than 5 million people in the U.S. and for which no cure exists.

The drug, called PMX205, prevented inflamed immune cells from gathering in brain regions with Alzheimer's lesions called amyloid plaques. Cell inflammation in these areas accelerates neuron damage, exacerbating the disease.

"We used a multidisciplinary approach combining an understanding of immunology and neurobiology to uncover a completely different target than other therapies," said Andrea Tenner, lead author of the study that led to the findings and a molecular biology & biochemistry professor at UCI.

Study results are reported in the July 15 edition of the Journal of Immunology.

For 12 weeks, Tenner and colleagues added PMX205 to the drinking water of mice genetically altered to develop age-related Alzheimer's-like symptoms. The treatment occurred at an age when plaques were accumulating in their brains.

Scientists gave the treated mice learning and memory tests and then examined their brains for evidence of the disease. Alzheimer's mice that were not given the drug performed significantly worse on the test than normal mice. But in all but one case the treated Alzheimer's mice performed almost as well as the normal mice. Those with the rescued cognitive ability had more than 50 percent fewer Alzheimer's lesions and inflammatory immune cells than the untreated diseased mice.

PMX53, a similar drug that can be taken orally, passed Phase 1 human clinical trials for safety with no major problems reported. Possible side effects include an increased susceptibility to some infections. PMX205 is a modified version that may be more potent for treatment of brain disorders.

"This approach may work even better if combined with treatments targeting other problems in the Alzheimer's brain," said Tenner, also a professor of pathology and neurobiology & behavior, as well as a member of UCI's Institute for Immunology and Institute for Memory Impairments and Neurological Disorders, or UCI MIND.


'/>"/>

Contact: Jennifer Fitzenberger
jfitzen@uci.edu
949-824-3969
University of California - Irvine
Source:Eurekalert

Related medicine news :

1. Petfinder.com Foundation Rescues 500 Shelters and Rescue Groups Nationwide with $1 Million Worth of Generators
2. Memory test and PET scans detect early signs of Alzheimers
3. Brown professor continues debate over recovered memory
4. More Evidence That Caffeine Can Jolt Memory
5. Caffeine reverses memory impairment in Alzheimers mice
6. On Memory, Older Americans Outsmart the English
7. Sleep May Be Essential for Long-Term Memory
8. Transplant drug stimulates immune memory
9. Generation of a severe memory-deficit mutant mouse by exclusively eliminating the kinase activity of CaMKIIalpha
10. Depression may increase Alzheimers risk in people with memory problems
11. Penn study demonstrates new way to boost immune memory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... ... May 29, 2017 , ... A New York high ... 6 month test of the effectiveness of Artificial Intelligence (AI) in helping nudge men ... health game,’ said Wayne Hartrick, President of the Canadian Men’s Health Foundation (CMHF), whose ...
(Date:5/28/2017)... Winter Haven, FL (PRWEB) , ... May 28, ... ... Physician Partners of America (PPOA), is proud to announce that Sheldon K. Cho, ... on comprehensive interventional pain management, a specialty that concentrates on minimally invasive techniques ...
(Date:5/27/2017)... ... ... From May 21-23, hearing healthcare professionals gained a competitive edge with training ... Syracuse Downtown Hotel in Syracuse, New York. , As EarQ’s technology partner, Oticon ... to help them stay ahead in the industry. At the event, EarQ members learned ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... a new educational seminar to focus on current legislative activity and the latest ... begin at 1 p.m. Sunday, Sept. 10, and will continue through Monday, Sept. ...
(Date:5/26/2017)... Nevada (PRWEB) , ... May 26, 2017 , ... ... produce the first ever copper, antimicrobial, mesh back 24/7 task chair specifically designed ... conference applications. “We are thrilled to partner with Cupron® to provide customers ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... -- Enterin Inc., a privately-held CNS pharmaceutical company based in ... treat Parkinson,s disease (PD), has enrolled the first patient in ... controlled, multicenter study involving patients with PD and taking place ... a 9-to-12-month period. The first stage is open label and ... sites include Denver , Boca ...
(Date:5/10/2017)... 10, 2017  The Corporate Whistleblower Center says, ... sleep therapy clinics to call us anytime at ... is involved in a substantial scheme to overbill ... from an employee of a medical equipment company ... to provide medical practice groups with extra generous incentives ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals ... ), a clinical-stage pharmaceutical company focused on the ... that the Canadian Intellectual Property Office has granted ... Oral Administration of Exenatide". The patent covers Oramed,s ... GLP-1 is an incretin hormone that ...
Breaking Medicine Technology: